Last reviewed · How we verify
Caplyta
At a glance
| Generic name | Caplyta |
|---|---|
| Also known as | lumateperone |
| Sponsor | University of Chicago |
| Target | D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Schizophrenia
Common side effects
- Somnolence/Sedation
- Dry Mouth
- Dizziness
- Nausea
Key clinical trials
- Caplyta in Borderline Personality Disorder (PHASE2)
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia (PHASE4)
- Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caplyta CI brief — competitive landscape report
- Caplyta updates RSS · CI watch RSS
- University of Chicago portfolio CI